Using therapies that induce and eliminate senescent cells to enhance melanoma treatment
Combining senescence-inducing and senolytic agents to improve melanoma therapy
This study is exploring a new way to help people with advanced melanoma by using a combination of treatments that make cancer cells easier for the immune system to spot and attack, especially for those whose tumors haven't responded well to other therapies.
Quick facts
| Grant type | R37 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ohio State University NIH-funded |
| Lab location | 1 site (Columbus, UNITED STATES) |
| Project ID | NIH-11052517 on NIH RePORTER |
What this research studies
This research investigates a novel approach to improve melanoma therapy by combining senescence-inducing agents with senolytic agents. The goal is to enhance the immune system's ability to recognize and attack melanoma cells, particularly in patients whose tumors are resistant to current treatments. By inducing cellular senescence, the therapy aims to increase inflammation and attract immune cells to the tumor site, while simultaneously targeting the senescent cells that may inhibit immune responses. This dual approach could potentially lead to better outcomes for patients with advanced melanoma.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with metastatic melanoma who have not responded to conventional therapies or immune checkpoint inhibitors.
Not a fit: Patients with early-stage melanoma or those who have not yet undergone treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for patients with metastatic melanoma, particularly those who do not respond to existing therapies.
How similar studies have performed: While the approach of combining senescence-inducing and senolytic agents is innovative, preliminary data suggest that enhancing immune responses through senescence may have shown promise in related studies.
Where this research is happening
Columbus, UNITED STATES
- Ohio State University — Columbus, United States (Active)
Researchers
- Principal investigator: Vilgelm, Anna E — Ohio State University
- Study coordinator: Vilgelm, Anna E
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.